Given the fact that the overexpression of ER2/ER1 in hormone-dependent malignancies, such as breast and prostate cancer, and also endometrial cancers, are associated with a high-grade tumoral process and predicts clinical outcomes, including the overall survival rate of patients, we can use the results of this study for the same purposes in patients with endometriosis (13, 35–37). The gene discussed is MIER1; the disease is prostate cancer.